Thermo Fisher Scientific Inc. (0R0H.L)
USD 428.58
(1.97%)
USD 428.58
(1.97%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 42.85 Billion USD | -4.58% |
| 2022 | 44.91 Billion USD | 14.55% |
| 2021 | 39.21 Billion USD | 21.71% |
| 2020 | 32.21 Billion USD | 26.14% |
| 2019 | 25.54 Billion USD | 4.86% |
| 2018 | 24.35 Billion USD | 16.45% |
| 2017 | 20.91 Billion USD | 14.47% |
| 2016 | 18.27 Billion USD | 7.71% |
| 2015 | 16.96 Billion USD | 0.45% |
| 2014 | 16.88 Billion USD | 29.02% |
| 2013 | 13.09 Billion USD | 4.64% |
| 2012 | 12.5 Billion USD | 6.69% |
| 2011 | 11.72 Billion USD | 8.69% |
| 2010 | 10.78 Billion USD | 6.72% |
| 2009 | 10.1 Billion USD | -3.7% |
| 2008 | 10.49 Billion USD | 7.71% |
| 2007 | 9.74 Billion USD | 157.05% |
| 2006 | 3.79 Billion USD | 44.0% |
| 2005 | 2.63 Billion USD | 19.36% |
| 2004 | 2.2 Billion USD | 5.19% |
| 2003 | 2.09 Billion USD | 0.52% |
| 2002 | 2.08 Billion USD | -4.65% |
| 2001 | 2.18 Billion USD | -4.05% |
| 2000 | 2.28 Billion USD | -7.72% |
| 1999 | 2.47 Billion USD | -36.11% |
| 1998 | 3.86 Billion USD | 8.69% |
| 1997 | 3.55 Billion USD | 21.34% |
| 1996 | 2.93 Billion USD | 32.85% |
| 1995 | 2.2 Billion USD | 39.24% |
| 1994 | 1.58 Billion USD | 26.85% |
| 1993 | 1.24 Billion USD | 31.69% |
| 1992 | 949 Million USD | 17.82% |
| 1991 | 805.5 Million USD | 13.77% |
| 1990 | 708 Million USD | 22.28% |
| 1989 | 579 Million USD | 15.66% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 10.34 Billion USD | -4.97% |
| 2024 Q3 | 10.59 Billion USD | 0.54% |
| 2024 Q2 | 10.54 Billion USD | 1.89% |
| 2023 Q2 | 10.68 Billion USD | -0.21% |
| 2023 Q3 | 10.57 Billion USD | -1.06% |
| 2023 Q4 | 10.88 Billion USD | 2.95% |
| 2023 FY | 42.85 Billion USD | -4.58% |
| 2023 Q1 | 10.71 Billion USD | -6.46% |
| 2022 Q4 | 11.45 Billion USD | 7.24% |
| 2022 Q1 | 11.81 Billion USD | 10.43% |
| 2022 Q2 | 10.97 Billion USD | -7.18% |
| 2022 FY | 44.91 Billion USD | 14.55% |
| 2022 Q3 | 10.67 Billion USD | -2.67% |
| 2021 FY | 39.21 Billion USD | 21.71% |
| 2021 Q1 | 9.9 Billion USD | -6.1% |
| 2021 Q2 | 9.27 Billion USD | -6.39% |
| 2021 Q3 | 9.33 Billion USD | 0.61% |
| 2021 Q4 | 10.7 Billion USD | 14.71% |
| 2020 Q1 | 6.23 Billion USD | -8.77% |
| 2020 Q4 | 10.55 Billion USD | 23.81% |
| 2020 Q2 | 6.91 Billion USD | 11.03% |
| 2020 FY | 32.21 Billion USD | 26.14% |
| 2020 Q3 | 8.52 Billion USD | 23.19% |
| 2019 Q1 | 6.12 Billion USD | -5.87% |
| 2019 Q2 | 6.31 Billion USD | 3.12% |
| 2019 Q3 | 6.27 Billion USD | -0.7% |
| 2019 Q4 | 6.82 Billion USD | 8.88% |
| 2019 FY | 25.54 Billion USD | 4.86% |
| 2018 Q1 | 5.85 Billion USD | -3.21% |
| 2018 Q4 | 6.5 Billion USD | 9.92% |
| 2018 FY | 24.35 Billion USD | 16.45% |
| 2018 Q3 | 5.92 Billion USD | -2.6% |
| 2018 Q2 | 6.07 Billion USD | 3.84% |
| 2017 Q3 | 5.11 Billion USD | 2.53% |
| 2017 Q1 | 4.76 Billion USD | -3.8% |
| 2017 Q2 | 4.99 Billion USD | 4.72% |
| 2017 Q4 | 6.04 Billion USD | 18.19% |
| 2017 FY | 20.91 Billion USD | 14.47% |
| 2016 FY | 18.27 Billion USD | 7.71% |
| 2016 Q1 | 4.29 Billion USD | -7.69% |
| 2016 Q3 | 4.49 Billion USD | -0.98% |
| 2016 Q4 | 4.95 Billion USD | 10.29% |
| 2016 Q2 | 4.53 Billion USD | 5.6% |
| 2015 FY | 16.96 Billion USD | 0.45% |
| 2015 Q1 | 3.91 Billion USD | -12.78% |
| 2015 Q2 | 4.27 Billion USD | 8.98% |
| 2015 Q3 | 4.12 Billion USD | -3.46% |
| 2015 Q4 | 4.65 Billion USD | 12.84% |
| 2014 Q4 | 4.49 Billion USD | 7.7% |
| 2014 Q1 | 3.9 Billion USD | 12.59% |
| 2014 Q2 | 4.32 Billion USD | 10.72% |
| 2014 Q3 | 4.17 Billion USD | -3.48% |
| 2014 FY | 16.88 Billion USD | 29.02% |
| 2013 Q2 | 3.24 Billion USD | 1.52% |
| 2013 Q1 | 3.19 Billion USD | -2.08% |
| 2013 FY | 13.09 Billion USD | 4.64% |
| 2013 Q4 | 3.46 Billion USD | 8.62% |
| 2013 Q3 | 3.19 Billion USD | -1.49% |
| 2012 Q3 | 3.08 Billion USD | -0.72% |
| 2012 Q2 | 3.1 Billion USD | 0.25% |
| 2012 Q1 | 3.1 Billion USD | -1.06% |
| 2012 FY | 12.5 Billion USD | 6.69% |
| 2012 Q4 | 3.25 Billion USD | 5.63% |
| 2011 Q4 | 3.13 Billion USD | 5.38% |
| 2011 Q1 | 2.72 Billion USD | -2.15% |
| 2011 Q2 | 2.89 Billion USD | 6.47% |
| 2011 Q3 | 2.97 Billion USD | 2.63% |
| 2011 FY | 11.72 Billion USD | 8.69% |
| 2010 FY | 10.78 Billion USD | 6.72% |
| 2010 Q4 | 2.78 Billion USD | 3.64% |
| 2010 Q3 | 2.68 Billion USD | 1.3% |
| 2010 Q2 | 2.64 Billion USD | -0.98% |
| 2010 Q1 | 2.67 Billion USD | -5.79% |
| 2009 Q4 | 2.83 Billion USD | 12.18% |
| 2009 FY | 10.1 Billion USD | -3.7% |
| 2009 Q2 | 2.48 Billion USD | 10.15% |
| 2009 Q3 | 2.53 Billion USD | 1.89% |
| 2009 Q1 | 2.25 Billion USD | -14.78% |
| 2008 Q4 | 2.64 Billion USD | 2.25% |
| 2008 FY | 10.49 Billion USD | 7.71% |
| 2008 Q1 | 2.55 Billion USD | -2.56% |
| 2008 Q2 | 2.7 Billion USD | 6.09% |
| 2008 Q3 | 2.58 Billion USD | -4.48% |
| 2007 Q1 | 2.33 Billion USD | 40.1% |
| 2007 Q4 | 2.62 Billion USD | 9.16% |
| 2007 FY | 9.74 Billion USD | 157.05% |
| 2007 Q2 | 2.38 Billion USD | 2.04% |
| 2007 Q3 | 2.4 Billion USD | 0.64% |
| 2006 FY | 3.79 Billion USD | 44.0% |
| 2006 Q1 | 684.28 Million USD | -7.63% |
| 2006 Q3 | 724.96 Million USD | 1.61% |
| 2006 Q4 | 1.66 Billion USD | 130.21% |
| 2006 Q2 | 713.46 Million USD | 4.26% |
| 2005 Q4 | 740.78 Million USD | 9.03% |
| 2005 FY | 2.63 Billion USD | 19.36% |
| 2005 Q3 | 679.41 Million USD | 3.95% |
| 2005 Q2 | 653.62 Million USD | 16.88% |
| 2005 Q1 | 559.2 Million USD | -8.83% |
| 2004 Q3 | 542.31 Million USD | 3.24% |
| 2004 Q1 | 582 Million USD | -0.24% |
| 2004 FY | 2.2 Billion USD | 5.19% |
| 2004 Q4 | 613.33 Million USD | 13.1% |
| 2004 Q2 | 525.3 Million USD | -9.74% |
| 2003 Q2 | 516.4 Million USD | 3.24% |
| 2003 Q3 | 497.11 Million USD | -3.74% |
| 2003 Q4 | 583.4 Million USD | 17.36% |
| 2003 Q1 | 500.2 Million USD | -12.05% |
| 2003 FY | 2.09 Billion USD | 0.52% |
| 2002 FY | 2.08 Billion USD | -4.65% |
| 2002 Q3 | 517.17 Million USD | 1.58% |
| 2002 Q2 | 509.11 Million USD | 3.62% |
| 2002 Q1 | 491.32 Million USD | -12.22% |
| 2002 Q4 | 568.74 Million USD | 9.97% |
| 2001 Q4 | 559.7 Million USD | 9.12% |
| 2001 FY | 2.18 Billion USD | -4.05% |
| 2001 Q3 | 512.94 Million USD | -5.44% |
| 2001 Q2 | 542.47 Million USD | -5.34% |
| 2001 Q1 | 573.08 Million USD | 16.68% |
| 2000 Q4 | 491.16 Million USD | -15.46% |
| 2000 FY | 2.28 Billion USD | -7.72% |
| 2000 Q3 | 580.95 Million USD | -4.68% |
| 2000 Q1 | 598.92 Million USD | -9.11% |
| 2000 Q2 | 609.48 Million USD | 1.76% |
| 1999 Q2 | 632.16 Million USD | 13.75% |
| 1999 FY | 2.47 Billion USD | -36.11% |
| 1999 Q1 | 555.75 Million USD | -44.34% |
| 1999 Q4 | 658.98 Million USD | 5.56% |
| 1999 Q3 | 624.29 Million USD | -1.25% |
| 1998 FY | 3.86 Billion USD | 8.69% |
| 1998 Q1 | 944.3 Million USD | -6.5% |
| 1998 Q2 | 947.8 Million USD | 0.37% |
| 1998 Q3 | 977.2 Million USD | 3.1% |
| 1998 Q4 | 998.4 Million USD | 2.17% |
| 1997 FY | 3.55 Billion USD | 21.34% |
| 1997 Q4 | 1 Billion USD | 10.99% |
| 1997 Q3 | 909.9 Million USD | 3.99% |
| 1997 Q2 | 875 Million USD | 14.6% |
| 1997 Q1 | 763.5 Million USD | -3.9% |
| 1996 FY | 2.93 Billion USD | 32.85% |
| 1996 Q1 | 635.1 Million USD | 0.84% |
| 1996 Q4 | 794.5 Million USD | 7.36% |
| 1996 Q2 | 745.8 Million USD | 17.43% |
| 1996 Q3 | 740 Million USD | -0.78% |
| 1995 Q2 | 528.7 Million USD | 10.49% |
| 1995 Q4 | 629.8 Million USD | 10.41% |
| 1995 Q3 | 570.4 Million USD | 7.89% |
| 1995 Q1 | 478.5 Million USD | 10.41% |
| 1995 FY | 2.2 Billion USD | 39.24% |
| 1994 Q2 | 395 Million USD | 12.7% |
| 1994 Q3 | 406.5 Million USD | 2.91% |
| 1994 Q4 | 433.4 Million USD | 6.62% |
| 1994 FY | 1.58 Billion USD | 26.85% |
| 1994 Q1 | 350.5 Million USD | 3.67% |
| 1993 Q2 | 300.4 Million USD | 2.6% |
| 1993 Q4 | 338.1 Million USD | 6.19% |
| 1993 Q1 | 292.8 Million USD | 0.41% |
| 1993 Q3 | 318.4 Million USD | 5.99% |
| 1993 FY | 1.24 Billion USD | 31.69% |
| 1992 Q3 | 242.9 Million USD | 15.61% |
| 1992 Q4 | 291.6 Million USD | 20.05% |
| 1992 Q1 | 204.4 Million USD | -7.18% |
| 1992 Q2 | 210.1 Million USD | 2.79% |
| 1992 FY | 949 Million USD | 17.82% |
| 1991 Q3 | 192 Million USD | -0.98% |
| 1991 Q4 | 220.2 Million USD | 14.69% |
| 1991 Q1 | 191.8 Million USD | -10.16% |
| 1991 FY | 805.5 Million USD | 13.77% |
| 1991 Q2 | 193.9 Million USD | 1.09% |
| 1990 Q3 | 181.5 Million USD | 6.64% |
| 1990 Q4 | 213.5 Million USD | 17.63% |
| 1990 Q1 | 133.3 Million USD | -15.58% |
| 1990 Q2 | 170.2 Million USD | 27.68% |
| 1990 FY | 708 Million USD | 22.28% |
| 1989 Q1 | 137.2 Million USD | -8.72% |
| 1989 FY | 579 Million USD | 15.66% |
| 1989 Q4 | 157.9 Million USD | 18.63% |
| 1989 Q2 | 150.8 Million USD | 9.91% |
| 1989 Q3 | 133.1 Million USD | -11.74% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| uniQure N.V. | 15.84 Million USD | -270410.636% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -159677.057% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -10631.528% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -499806.684% |
| bluebird bio, Inc. | 29.49 Million USD | -145192.742% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -204292.407% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | 78.12 Million USD | -54758.364% |
| IQVIA Holdings Inc. | 14.98 Billion USD | -186.018% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | -1031.296% |
| Myriad Genetics, Inc. | 678.4 Million USD | -6217.364% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | -2171.051% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -6954.406% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 70.975% |
| Waters Corporation | 2.95 Billion USD | -1349.627% |
| Biogen Inc. | 9.83 Billion USD | -335.733% |
| Nektar Therapeutics | 90.12 Million USD | -47454.426% |
| Perrigo Company plc | 4.65 Billion USD | -820.547% |
| Dynavax Technologies Corporation | 232.28 Million USD | -18350.259% |
| Illumina, Inc. | 4.5 Billion USD | -851.532% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -3604357.527% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -33633.982% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | -1671.517% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -24218.512% |
| Evolus, Inc. | 202.08 Million USD | -21107.413% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -137046.789% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | -226.724% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -36739.617% |
| FibroGen, Inc. | 147.75 Million USD | -28906.037% |
| Agilent Technologies, Inc. | 6.83 Billion USD | -527.206% |
| OPKO Health, Inc. | 863.49 Million USD | -4863.202% |
| Homology Medicines, Inc. | -6.65 Million USD | 644469.268% |
| Geron Corporation | 237 Thousand USD | -18083022.363% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -2244.1% |
| Exelixis, Inc. | 1.83 Billion USD | -2241.646% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -118044.728% |
| Zoetis Inc. | 8.54 Billion USD | -401.603% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -15737.768% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -1224385.714% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | -334.25% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -5341.143% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -3346.936% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -8784.581% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -5068.145% |
| Blueprint Medicines Corporation | 249.38 Million USD | -17085.42% |
| Insmed Incorporated | 305.2 Million USD | -13941.899% |
| TG Therapeutics, Inc. | 233.66 Million USD | -18241.45% |
| Incyte Corporation | 3.69 Billion USD | -1059.661% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -3984.342% |